In the highly regulated world of pharmaceutical manufacturing, few documents carry as much weight as the technical reports published by the Parenteral Drug Association (PDA). Among these, PDA Technical Report No. 82 (TR-82) stands as a cornerstone for professionals involved in biopharmaceutical manufacturing, particularly those working with mammalian cell culture processes.
If you have searched for the term "PDA Technical Report 82 PDF," you are likely looking for deep technical insights into low bioburden, sterile filtration, or process validation. This article provides an exhaustive overview of TR-82, its significance, how to access a legitimate copy, and why it is indispensable for modern bioprocessing.
As per TR 82 Section 7, add a known quantity of endotoxin (e.g., 100 EU/mL) to your product at time zero. Test for recovery at: pda technical report 82 pdf
If recovery falls below 50% at any time point without a parallel drop in a control buffer → LER is confirmed.
The primary goal of TR 82 is to provide a scientific, risk-based approach to ensuring that equipment (such as glass vials, ampoules, and containers) is free from pyrogens before filling. T = 0 (baseline) T = 1 day,
Key areas covered include:
Apply TR 82’s risk matrix to all parenteral products. High-risk includes: If recovery falls below 50% at any time
The document is a proprietary technical report owned by the PDA.
Summaries of FDA, EMA, and PMDA expectations. Notably, the FDA’s 2012 guidance "Pyrogen and Endotoxins Testing" directly references TR 82.
To appreciate the report, one must understand the mechanism. Endotoxins (lipopolysaccharides from Gram-negative bacteria) exist as complex aggregates. The LAL test detects active lipid A portions. TR 82 identifies three primary mechanisms for LER: